From Facebook

"Anaphylaxis is a notorious type 2 immune response which may result in a systemic response and lead to death. A precondition for the unfolding of the anaphylactic shock is the secretion of inflammatory mediators from mast cells in response to an allergen, mostly through activation of the cells via the IgE-dependent pathway.

While mast cells are specialized secretory cells that can secrete through a variety of exocytic modes, the most predominant mode exerted by the mast cell during anaphylaxis is compound exocytosis—a specialized form of regulated exocytosis where secretory granules fuse to one another.

Here, we review the modes of regulated exocytosis in the mast cell and focus on compound exocytosis. "

Future Needs in Mast Cell Biology

September 2019 International Journal of Molecular Sciences 20(18):4397 DOI:
10.3390/ijms20184397

https://www.researchgate.net/publication/335699582_Future_Needs_in_Mast_Cell_Biology/fulltext/5d76565a299bf1cb8093e36a/Future-Needs-in-Mast-Cell-Biology.pdf

Mast Cells: Fascinating but Still Elusive after 140 Years from Their Discovery

Gilda Varricchi, Gianni Marone
January 2020
International Journal of Molecular Sciences 21(2):464
DOI: 10.3390/ijms21020464

https://www.researchgate.net/publication/338555468_Mast_Cells_Fascinating_but_Still_Elusive_after_140_Years_from_Their_Discovery/fulltext/5e1c8c74299bf10bc3abd187/Mast-Cells-Fascinating-but-Still-Elusive-after-140-Years-from-Their-Discovery.pdf

When should you go out of your house 
???

Individuals taking class of steroid medications at high risk for COVID-19

Released: 31-Mar-2020 12:00 PM EDT
Source Newsroom: Endocrine Society

A potentially exciting endocrine-connected observation is the elucidation of the mechanism of entry of SARS-CoV-2 into cells. Here, angiotensin-converting enzyme 2 (ACE2) is now established as the SARS-CoV receptor (9) but with conflicting data as to its translational relevance.

It has been suggested that angiotensin-converting enzyme inhibitors/angiotensin receptor blockers might increase susceptibility and severity to COVID-19 through upregulation of ACE2 and thereby possibly explain the overrepresentation of hypertensive patients in patients dying from COVID-19 (10). Upregulation of ACE2 might also explain the poor outcome in smokers versus nonsmokers, but it is important to stress that these are preliminary reports and should not result in changing prescribed medications at this stage (11).

APN01 is a recombinant human ACE2 developed by APEIRON for the treatment of acute lung injury, acute respiratory distress syndrome, and pulmonary arterial hypertension; by slowing viral entry into cells and viral spread, it may be beneficial, and clinical trials are underway (12).

Conversely, angiotensin II is known to stimulate alveolar epithelial cell apoptosis, and inhibition of this with angiotensin receptor 1 blockers such as losartan might reduce mortality from acute respiratory distress syndrome in COVID-19 infection (13).

Perhaps justifying greater excitement is the downstream transmembrane protease serine 2 required for SARS-CoV-2 viral spike protein priming and onward transmission (14).

Camostat mesylate, a transmembrane protease serine 2 inhibitor, has been approved in Japan for the treatment of pancreatic inflammation and when tested on SARS-CoV-2 isolated from a patient prevented the entry of the virus into lung cells.

Endocrine-related targets are at the forefront of discovery science as we collectively tackle this pandemic."

https://academic.oup.com/jcem/article/105/5/dgaa148/5814115

Good news, increases ARDS survival from 20% to 50% and improve collateral damage in less severe cases. BARDA FDA fast track.

:star::star::star:
Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of Nebraska Medical Center

“Disease spread through both direct (droplet and person-to-person) as well as indirect contact (contaminated objects and airborne transmission) are indicated, supporting the use of airborne isolation precautions.”

"Although this study did not employ any size-fractionation techniques in order to determine the size range of SARS-CoV-2 droplets and particles, the data is suggestive that viral aerosol particles are produced by individuals that have the COVID-19 disease, even in the absence of cough.

First, in the few instances where the distance between individuals in isolation and air sampling could be confidently maintained at greater than 6 ft, 2 of the 3 air samples were positive for viral RNA. Second, 66.7% of hallway air samples indicate that virus-containing particles were being transported from the rooms to the hallway during sampling activities. It is likely that the positive air samples in the hallway were cause by viral aerosol particles transported by personnel exiting the room (16,17). Finally, personal air samplers worn by sampling personnel were all positive for SARS-CoV-2, despite the absence of cough by most patients while sampling personnel were present.

Recent literature investigating human expired aerosol indicates that a significant fraction of human expired aerosol is less than 10 ”m in diameter across all types of activity (e.g. breathing, talking, and coughing; 18) and that upper respiratory illness increases production of aerosol particles (less than 10 ”m; 19). Taken together these results suggest that virus expelled from infected individuals, including from those who are only mildly ill, may be transported by aerosol processes in their local environment, potentially even in the absence of cough or aerosol generating procedures.

Further, a recent study of SARS-CoV-2 in aerosol and deposited on surfaces, indicates infectious aerosol may persist for several hours and on surfaces for as long as 2 days (20).

Despite wide-spread environmental and limited SARS-CoV-2 aerosol contamination associated with hospitalized and mildly ill individuals, effective implementation of airborne isolation precautions including N95 filtering facepiece respirators and powered air purifying respirator use adequately protected health care workers, in the NQU and NBU facilities, preventing health care worker infections.

Health care workers were closely monitored and screened for COVID-19 suggesting the value in implementing IPC protocols that maintain airborne isolation standards including respiratory protection and include routine systematic environmental cleaning and disinfection of patient care areas and surrounding environments."

I’ve had queries about reinfection rates. Here is one very recent study.

Simple discussion of Epidemiological Mortality Modeling 101 and why early in an outbreak it’s hard to get good estimates.and model convergence. “All models are wrong, some of the however may be useful”. :thinking::star::+1:

Flash!!!:star::star::star:

For Immediate Release:April 01, 2020

The U.S. Food and Drug Administration today announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac). The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity. As a result of this immediate market withdrawal request, ranitidine products will not be available for new or existing prescriptions or OTC use in the U.S.

Surviving Sepsis

Abstract

Background:

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed.

Methods:

We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations.

Results:

The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which four are best practice statements, nine are strong recommendations, and 35 are weak recommendations. No recommendation was provided for six questions. The topics were: 1) infection control, 2) laboratory diagnosis and specimens, 3) hemodynamic support, 4) ventilatory support, and 5) COVID-19 therapy.

Conclusion:

The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new evidence in further releases of these guidelines.

https://journals.lww.com/ccmjournal/Abstract/onlinefirst/Surviving_Sepsis_Campaign__Guidelines_on_the.95707.aspx

Modern Problems, Same Ol’ Same Ol’ for all us Masties.

Any Scouts​:fleur_de_lis::grin: April 1st​:wink:

IgG reactions

https://www.jci.org/articles/view/45232

http://bit.ly/2wPvheH

The next major wave (RED) where people will die. Please stay home.

Dose makes the poison, limit exposure, under 6 feet, less than 6 seconds.

Here’s some info about H2 agonist since all Ranitidine (Zantac) has been recalled.

What are the differences between the H2‐receptor antagonists?

W. SCHUNACK

First published:April 1987

https://doi.org/10.1111/j.1365-2036.1987.tb00658.x

SUMMARY

The H2‐receptor antagonists which are used for ulcer therapy fall into four main structural classes. Cimetidine is an imidazole derivative; ranitidine belongs to the basically substituted furans, famotidine is a member of the guanidinothiazole group; and roxatidine belongs to the aminoalkylphenoxy series. Famotidine is the most potent, selective H2‐receptor antagonist yet available for ulcer therapy. On a weight basis, famotidine is approximately eight times more potent than ranitidine and 40 times more potent than cimetidine. Cimetidine, ranitidine and famotidine are competitive antagonists, while the long‐acting H2‐receptor antagonists, e.g. loxtidine and lamitidine, are insurmountable H2‐receptor blockers. Famotidine has a longer duration of action than either ranitidine or cimetidine. Because famotidine does not interact with cytochrome P‐450 of the hepatic enzyme system, it does not appear to affect the metabolism of drugs metabolized by this system. The overall number of side‐effects of the H2‐receptor antagonists is in the range of 2–3% and no irreversible adverse effects are known. Famotidine has been found to be generally well tolerated. In a first post‐marketing study, the number of patients with side‐effects was only 0.43%. Side‐effects such as headache, dizziness, constipation and diarrhoea have been observed only occasionally. Thus, famotidine is a safe and potent H2‐receptor blocker of acid secretion.

https://www.nature.com/articles/srep41721